These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 7975362)

  • 1. [Treatment of iron overload states with oral administration of the chelator agent, L1 (Deferiprone)].
    Cermák J; Brabec V
    Vnitr Lek; 1994 Sep; 40(9):586-90. PubMed ID: 7975362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.
    Kontoghiorghes GJ; Aldouri MA; Hoffbrand AV; Barr J; Wonke B; Kourouclaris T; Sheppard L
    Br Med J (Clin Res Ed); 1987 Dec; 295(6612):1509-12. PubMed ID: 3122880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Current possibilities in the therapy of iron overload].
    Cermák J
    Vnitr Lek; 1994 Sep; 40(9):605-8. PubMed ID: 7975366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zinc concentration in patients with iron overload receiving oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one or desferrioxamine.
    al-Refaie FN; Wonke B; Wickens DG; Aydinok Y; Fielding A; Hoffbrand AV
    J Clin Pathol; 1994 Jul; 47(7):657-60. PubMed ID: 8089225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1).
    Rombos Y; Tzanetea R; Konstantopoulos K; Simitzis S; Zervas C; Kyriaki P; Kavouklis M; Aessopos A; Sakellaropoulos N; Karagiorga M; Kalotychou V; Loukopoulos D
    Haematologica; 2000 Feb; 85(2):115-7. PubMed ID: 10681716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iron chelation therapy.
    Hoffbrand AV; Wonke B
    J Intern Med Suppl; 1997; 740():37-41. PubMed ID: 9350180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New concepts of iron and aluminium chelation therapy with oral L1 (deferiprone) and other chelators. A review.
    Kontoghiorghes GJ
    Analyst; 1995 Mar; 120(3):845-51. PubMed ID: 7741239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major.
    al-Refaie FN; Wonke B; Hoffbrand AV; Wickens DG; Nortey P; Kontoghiorghes GJ
    Blood; 1992 Aug; 80(3):593-9. PubMed ID: 1638018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease.
    Collins AF; Fassos FF; Stobie S; Lewis N; Shaw D; Fry M; Templeton DM; McClelland RA; Koren G; Olivieri NF
    Blood; 1994 Apr; 83(8):2329-33. PubMed ID: 8161801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined oral and parenteral iron chelation in beta thalassaemia major.
    Balveer K; Pyar K; Wonke B
    Med J Malaysia; 2000 Dec; 55(4):493-7. PubMed ID: 11221163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators.
    Kolnagou A; Kontoghiorghes GJ
    Hemoglobin; 2006; 30(2):239-49. PubMed ID: 16798649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload.
    Kontoghiorghes GJ; Aldouri MA; Sheppard L; Hoffbrand AV
    Lancet; 1987 Jun; 1(8545):1294-5. PubMed ID: 2884415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analytic review of the clinical effectiveness of oral deferiprone (L1).
    Addis A; Loebstein R; Koren G; Einarson TR
    Eur J Clin Pharmacol; 1999 Mar; 55(1):1-6. PubMed ID: 10206077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy of desferrioxamine, deferiprone and in combination on iron chelation in thalassemic children.
    Gomber S; Saxena R; Madan N
    Indian Pediatr; 2004 Jan; 41(1):21-7. PubMed ID: 14767084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary iron excretion depends on the mode of administration of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with homozygous beta-thalassemia.
    Fassos FF; Klein J; Fernandes D; Matsui D; Olivieri NF; Koren G
    Clin Pharmacol Ther; 1994 Jan; 55(1):70-5. PubMed ID: 8299320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Long-term treatment of patients with transfusion hemosiderosis using oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1)].
    Goudsmit R
    Ned Tijdschr Geneeskd; 1991 Nov; 135(45):2133-6. PubMed ID: 1944690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of deferiprone in patients with β-thalassaemia: impact of splenectomy and iron status.
    Limenta LM; Jirasomprasert T; Jittangprasert P; Wilairat P; Yamanont P; Chantharaksri U; Fucharoen S; Morales NP
    Clin Pharmacokinet; 2011 Jan; 50(1):41-50. PubMed ID: 21028920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in transferrin saturation after treatment with the oral iron chelator deferiprone in patients with iron overload.
    al-Refaie FN; De Silva CE; Wonke B; Hoffbrand AV
    J Clin Pathol; 1995 Feb; 48(2):110-4. PubMed ID: 7745107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). I. Iron chelation and metabolic studies.
    Kontoghiorghes GJ; Bartlett AN; Hoffbrand AV; Goddard JG; Sheppard L; Barr J; Nortey P
    Br J Haematol; 1990 Oct; 76(2):295-300. PubMed ID: 2094333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term treatment with deferiprone in a L1 veteran.
    Meo A; Ruggeri A; La Rosa MA; Zanghì L; Kordes U; Fischer R
    Eur J Haematol; 2005 Jun; 74(6):523-5. PubMed ID: 15876257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.